Emergent BioSolutions to Webcast Presentation at JPMorgan Healthcare Conference

ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the 29th Annual JPMorgan Healthcare Conference in San Francisco on Wednesday, January 12, 2011 at 11:30 AM Pacific. During the presentation, a member of the company’s senior management team will provide a corporate overview, including a discussion of product development programs, corporate activities, preliminary 2010 financial results and financial guidance for 2011.

A webcast of this presentation will be available both live and by replay, accessible from the company’s website www.emergentbiosolutions.com under “Investors”.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a global biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information may be found at www.emergentbiosolutions.com.



CONTACT:

Emergent BioSolutions Inc.
Investors:
Robert G. Burrows, 301-795-1877
Vice President, Investor Relations
[email protected]
or
Media:
Tracey Schmitt, 301-795-1800
Director, Corporate Communications
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Just three days after Daiichi Sankyo’s Xospata challenger scored approval in Japan for a form of acute myeloid leukemia, the FDA has declined to clear the drug…

Martin Shkreli settled a lawsuit he filed against his former Retrophin colleagues, claiming they “unceremoniously and illegally” ousted him in 2014.

The appointment ends a 20-year stint at Theravance Biopharma and its parent company that culminated in Sharath Hegde rising to head of research.